FDA Approved: ALHEMO — Supplemental Application (Novo Nordisk)

View source ↗

Summary

FDA approved a supplemental application for ALHEMO (Concizumab) from Novo Nordisk, expanding the product's regulatory status.

Upgrade for the full analysis, importance score, and drug timeline.

Diseases / indications

• Hemophilia

Drugs mentioned

• ALHEMO (Concizumab)

Snippet

SUPPL AP for ALHEMO (CONCIZUMAB)